QMSR Inspections

A New Era of FDA Medical Device Inspections

The U.S. Food and Drug Administration has fundamentally transformed how medical device manufacturers are inspected.

With the implementation of the Quality Management System Regulation (QMSR) and the updated Compliance Program 7382.850, FDA inspections have shifted from a checklist-based approach to a risk-driven, data-informed, and lifecycle-based evaluation model.

From QSIT to QMSR

A Fundamental Shift in Inspection Philosophy

For decades, FDA inspections were guided by the Quality System Inspection Technique (QSIT). It was quality subsystem-based, checklist-oriented, and predictable in structure.

That model has now been replaced. QSIT is no longer in use.

Under QMSR, inspections are risk-based, investigator-driven, systemwide, and focused on decision making and outcomes.

This is not an incremental update; it is a complete transformation in how FDA evaluates compliance.

How FDA Now Conducts Inspections

FDA inspections are risk-driven, flexible, investigator-led, and data-informed. The inspection scope can expand rapidly based on findings, and a single issue can trigger full system exposure.

From Subsystems to System-Wide Evaluation

FDA no longer inspects isolated areas such as CAPA or complaints. Every inspection now evaluates the entire quality system.

From Checklists to Risk-Based Investigation

Investigators no longer follow rigid inspection paths. They follow risk signals, data trends, and observed issues.

From Documentation to Decision-Making

FDA is no longer asking “Do you have procedures?” The agency is now asking “Are your decisions appropriate, justified, and effective?”

From Point-in-Time Audits to Lifecycle Evaluation

Inspections now cover the Total Product Lifecycle (TPLC), from design and development through manufacturing and process control, distribution, postmarket surveillance, feedback, and corrective action.

This is a continuous system evaluation. Not a snapshot.

From Reactive to Predictive Oversight

FDA investigators now arrive with information about your company gleaned from complaint data, MDRs, recall and field data, and inspection history. And inspections are now hypothesis driven.